By Maxx Chatsko The decision forced a key supplier for a drug component to reduce 2022 guidance. Pfizer (PFE) – Get Pfizer Inc. Report may have used artificial intelligence and advanced computational modeling to more quickly develop Paxlovid, but that never guaranteed commercial success. Indeed, the pandemic star may have quietly hinted at reduced expectations for its oral antiviral pill. That’s bad news for a popular growth stock. Codexis (CDXS) – Get Codexis Inc. Report announced a restructured supply agreement for a key ingredient for Paxlovid. Specifically, Codexis supplies an enzyme that …